Cargando…

Dendritic cell vaccine treatment for indolent B cell non-hodgkin lymphoma: clinical trial in progress

Detalles Bibliográficos
Autores principales:	Lin, Yi, Atwell, Thomas, Weisbrod, Adam, Maas, Mary, Armstrong, Adam, Deeds, Michael, Bulur, Peggy, Gustafson, Michael, Zhang, Zhe, Porrata, Louis, Markovic, Svetomir, Johnston, Patrick, Micallef, Ivana, Inwards, David, Colgan, Joseph, Ansell, Stephen, Gastineau, Dennis, Dietz, Allan, Witzig, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288739/ http://dx.doi.org/10.1186/2051-1426-2-S3-P76

Ejemplares similares

Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma
por: Holtan, Shernan G, et al.
Publicado: (2006)

Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin lymphoma
por: Porrata, Luis F, et al.
Publicado: (2015)

Interleukin-15 Affects Patient Survival through Natural Killer Cell Recovery after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphomas
por: Porrata, Luis F., et al.
Publicado: (2010)

Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation
por: Porrata, Luis F., et al.
Publicado: (2013)

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma
por: Porrata, L F, et al.
Publicado: (2013)

Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation
por: Porrata, Luis F., et al.
Publicado: (2015)

Long‐term outcome of immunologic autograft engineering
por: Porrata, Luis F., et al.
Publicado: (2022)

Lymphoma monocyte crosstalk via HSP27 to promote immune suppression and chemotherapy resistance
por: Zhang, Zhe, et al.
Publicado: (2014)

Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant
por: Tun, Aung M., et al.
Publicado: (2023)

Tumor monocyte cross talk promotes lymphoma cell resistance to chemotherapy
por: Zhang, Zhe (Jenny), et al.
Publicado: (2013)

Expression profiling of suppressive monocytes (CD14+HLA-DRlow/neg) in cancer patients
por: Cordes, Stefan F, et al.
Publicado: (2013)

Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma
por: Markovic, Svetomir N, et al.
Publicado: (2006)

High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)
por: Witzig, T E, et al.
Publicado: (2017)

CD34(+) cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies
por: Holtan, S G, et al.
Publicado: (2010)

Predicting Peripheral Blood Stem Cell Harvest Failure Using Circulating CD34 Levels: Developing Target-Based Cut-Points for Early Intervention
por: Sinha, S, et al.
Publicado: (2010)

A method for non-overlapping identification of human myeloid derived suppressor cells
por: Gustafson, Michael, et al.
Publicado: (2014)

Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study
por: Desai, Sanjal H., et al.
Publicado: (2021)

IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/−) monocytes in B-cell non-Hodgkin lymphoma
por: Xiu, B, et al.
Publicado: (2015)

Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14(+)HLA-DR(lo/neg) Cells): The Gateway to Improved Responses
por: Laborde, Rebecca R., et al.
Publicado: (2014)

Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective
por: Villasboas, Jose Caetano, et al.
Publicado: (2016)

Immune independent crosstalk between lymphoma and myeloid suppressor CD14(+)HLA-DR(low/neg) monocytes mediates chemotherapy resistance
por: Zhang, Zhe (Jenny), et al.
Publicado: (2015)

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
por: Witzig, T E, et al.
Publicado: (2011)

Ten-color, whole blood flow cytometric analysis of human myeloid subsets; implications for immune monitoring in cancer patients
por: Gustafson, Michael P, et al.
Publicado: (2013)

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts
por: Desai, Sanjal H., et al.
Publicado: (2022)

Immunotherapy in indolent Non-Hodgkin's Lymphoma
por: Amhaz, Ghid, et al.
Publicado: (2022)

Phase I Trial of Autologous Hematopoietic Stem Cell Transplantation with Escalating Doses of Topotecan Combined with Cyclophosphamide and Carboplatin in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma
por: Litzow, MR, et al.
Publicado: (2009)

Using whole immune system characterization (immune profiling) to identify immune biomarkers to determine patient selection, dosing, and efficacy of new immune therapies
por: Gustafson, Michael, et al.
Publicado: (2015)

Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas
por: Minson, Adrian, et al.
Publicado: (2022)

The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
por: Aldoss, Ibrahim T, et al.
Publicado: (2009)

Endogenous Heat‐Shock Protein Induction with or Without Radiofrequency Ablation or Cryoablation in Patients with Stage IV Melanoma
por: Domingo‐Musibay, Evidio, et al.
Publicado: (2017)

Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome
por: Dispenzieri, Angela, et al.
Publicado: (2008)

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas
por: Briski, R, et al.
Publicado: (2014)

Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma
por: Tageja, Nishant
Publicado: (2011)

Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma
por: Weide, Rudolf
Publicado: (2008)

Role of antibody-based therapy in indolent non-Hodgkin's lymphoma
por: Willard, Patrick, et al.
Publicado: (2021)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

A Method for Identification and Analysis of Non-Overlapping Myeloid Immunophenotypes in Humans
por: Gustafson, Michael P., et al.
Publicado: (2015)

Comparison of CT, PET, and PET/CT for Staging of Patients with Indolent Non-Hodgkin’s Lymphoma
por: Fueger, Barbara J., et al.
Publicado: (2009)

End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET
por: Chohan, Karan L., et al.
Publicado: (2022)

Novel strategy for manufacturing autologous dendritic cell/allogeneic tumor lysate vaccines for glioblastoma
por: Parney, Ian F, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mcob4u4b4c7gdfdnda4siih64r